Second phase III trial of MED2002 for the Treatment of Erectile Dysfunction (ED)
Latest Information Update: 12 Sep 2019
At a glance
- Drugs Nitroglycerin (Primary)
- Indications Erectile dysfunction
- Focus Registrational; Therapeutic Use
- Sponsors Futura Medical
- 11 Sep 2019 According to a Futura Medical media release, he protocols for this study will be the same as for "FM57" initially but will be informed by the receipt and analysis of the first Phase 3 data and adapted accordingly, if necessary, via regulatory amendments.
- 11 Sep 2019 According to a Futura Medical media release, the company is currently undertaking pre-recruitment start-up activities in order to commence patient enrolment in H1 2020.
- 14 Mar 2018 According to a Futura Medical media release, Interim pharmacokinetic data indicates that at least two higher strength doses of MED2002 are eligible for the planned Phase III studies (this and profile 283164) compared with the dose used in the successful Phase II study.